Cytokinetics CYTK Income Statement (2010-2026)

NASDAQ CYTK
$72.59 -1.36 (-1.84%)
As of: Sep 4, 2026 · 2:22 PM EDT
Reported Financials

Cytokinetics Quarterly Income Statement

Periods 65 quarters
Latest Jun 2026

Cytokinetics reported revenue of $28.62M and net income of -$200.98M for the quarter ended Jun 2026, down 57.1% year over year. This income statement covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
5.44M55.60M1.15M88.97M2.52M1.96M4.61M0.87M0.38M1.67M0.83M0.25M0.46M15.00M1.58M66.77M1.94M17.75M19.36M28.62M
Cost of RevenueCost of Rev
0.16M2.73M
Gross Profit
1.58M66.77M19.20M25.89M
Operating items
Research & DevelopmentR&D
48.44M43.50M45.94M57.13M62.73M75.02M79.42M83.19M82.53M84.98M81.57M79.60M84.61M93.63M98.26M110.14M99.23M104.40M95.53M97.81M
Selling, General & AdministrativeSG&A
26.20M33.81M33.07M42.72M48.22M53.97M49.66M39.72M40.11M44.11M45.50M50.82M56.65M62.34M57.37M65.72M69.46M91.72M104.90M104.40M
Restructuring CostsRestructuring
Other Operating ExpensesOther Opex
1.58M2.42M2.55M5.59M
Operating ExpensesOpex
74.64M77.30M79.00M99.84M110.96M128.99M129.09M122.92M122.64M129.09M127.07M130.42M141.26M155.97M157.21M178.28M168.69M196.12M202.97M207.80M
Operating IncomeOp. Inc
-69.20M-21.70M-77.86M-10.87M-108.44M-127.03M-124.47M-122.05M-122.27M-127.42M-126.23M-130.17M-140.80M-139.04M-155.63M-111.51M-166.75M-178.37M-183.62M-179.17M
EBIT
-69.20M-21.70M-77.86M-10.87M-108.44M-127.03M-124.47M-122.05M-122.27M-127.42M-126.23M-130.17M-140.80M-139.04M-155.63M-111.51M-166.75M-178.37M-183.62M-179.17M
Non-operating items
Non Operating Interest Expenses
4.16M4.22M6.56M2.81M6.80M7.06M6.96M7.04M7.14M7.16M7.10M12.73M8.93M8.94M11.08M11.35M14.27M
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
-2.69M-22.25M-0.60M-15.20M1.30M3.90M-14.60M-2.80M17.70M-1.60M2.40M
Non Operating IncomeNon Op. Inc.
0.23M-0.38M0.41M0.86M4.14M5.92M6.42M6.78M6.84M7.59M7.91M11.55M17.05M15.01M13.70M13.00M10.25M11.47M11.02M13.94M
Net income details
EBT
-73.36M-25.92M-84.42M-13.68M-115.25M-134.09M-131.43M-129.09M-129.40M-134.58M-133.34M-142.90M-149.73M-147.98M-155.63M-122.59M-178.11M-192.64M-183.62M-179.17M
Tax ProvisionsTaxes
Profit After TaxPAT
-76.13M-31.37M-89.44M-19.82M-143.38M-135.41M-131.29M-128.64M-129.42M-136.90M-135.64M-143.32M-160.54M-150.02M-161.38M-136.07M-306.18M-182.44M-206.03M-200.98M
Income from Continuing OperationsIncome (Continuing)
-73.36M-25.92M-84.42M-13.68M-115.25M-134.09M-131.43M-129.09M-129.40M-134.58M-133.34M-142.90M-149.73M-147.98M-155.63M-122.59M-178.11M-192.64M-183.62M-179.17M
Consolidated Net IncomeConsol Net Inc.
-73.36M-25.92M-84.42M-13.68M-115.25M-134.09M-131.43M-129.09M-129.40M-134.58M-133.34M-142.90M-149.73M-147.98M-155.63M-122.59M-178.11M-192.64M-183.62M-179.17M
Income towards Parent CompanyParent Net Inc
-73.36M-25.92M-84.42M-13.68M-115.25M-134.09M-131.43M-129.09M-129.40M-134.58M-133.34M-142.90M-149.73M-147.98M-155.63M-122.59M-178.11M-192.64M-183.62M-179.17M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-73.36M-25.92M-84.42M-13.68M-115.25M-134.09M-131.43M-129.09M-129.40M-134.58M-133.34M-142.90M-149.73M-147.98M-155.63M-122.59M-178.11M-192.64M-183.62M-179.17M
Additional items
EPS (Basic)
-0.91-0.34-0.99-0.16-1.23-1.49-1.38-1.35-1.35-1.39-1.31-1.31-1.27-1.32-1.31-1.03-1.48-1.60-1.49-1.36
EPS (Diluted)
-0.91-0.34-0.99-0.16-1.23-1.49-1.38-1.35-1.35-1.39-1.31-1.31-1.27-1.32-1.31-1.03-1.48-1.60-1.49-1.36
Shares Outstanding
80.33M76.89M85.00M85.73M93.76M89.83M95.16M95.75M95.75M96.52M101.92M109.24M117.69M111.98M118.50M119.46M119.98M120.10M123.27M132.09M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
80.33M76.89M85.00M85.73M93.76M89.83M95.16M95.75M95.75M96.52M101.92M109.24M117.69M111.98M118.50M119.46M119.98M120.10M123.27M132.09M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
83.88M84.80M85.65M94.14M94.63M94.83M95.64M96.00M101.64M104.85M117.66M118.01M118.21M119.43M119.66M122.26M122.94M124.43M139.02M
EBITDA
-69.20M-21.70M-77.86M-10.87M-108.44M-127.03M-124.47M-122.05M-122.27M-127.42M-126.23M-130.17M-140.80M-139.04M-155.63M-111.51M-166.75M-178.37M-183.62M-179.17M
Interest ExpensesInt Expense
4.16M4.22M6.56M2.81M6.80M7.06M6.96M7.04M7.14M7.16M7.10M12.73M8.93M8.94M11.08M11.35M14.27M
Tax Rate